The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 25, 2024
Filed:
Apr. 06, 2023
Applicant:
Proqr Therapeutics Ii B.v., Leiden, NL;
Inventors:
Janne Juha Turunen, Leiden, NL;
Petra Geziena De Bruijn, Leiden, NL;
Bart Klein, Leiden, NL;
Roxana Simona Redis, Leiden, NL;
Lenka Van Sint Fiet, Leiden, NL;
Assignee:
ProQR Therapeutics II B.V., Leiden, NL;
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/11 (2006.01); A61K 31/7125 (2006.01); C12N 15/10 (2006.01); C12Q 1/68 (2018.01);
U.S. Cl.
CPC ...
C12N 15/111 (2013.01); A61K 31/7125 (2013.01); C12N 15/102 (2013.01); C12N 2310/11 (2013.01); C12N 2310/321 (2013.01); C12N 2310/3521 (2013.01); C12N 2310/3527 (2013.01); C12N 2320/30 (2013.01);
Abstract
The invention relates to antisense oligonucleotides that are capable of bringing about specific editing of a target nucleotide (adenosine) in a target RNA in a eukaryotic cell, wherein said oligonucleotide does not, in itself, form an intramolecular hairpin or stem-loop structure, and wherein said oligonucleotide comprises a cytidine (a non-complementary nucleotide) or a uridine in a position opposite to the target adenosine to be edited in the target RNA region.